Tioga Pharmaceuticals, Inc.

Stuart J.M. Collinson, Ph.D.
Chairman and Chief Executive Officer

Dr. Collinson is a partner at Forward Ventures. Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences Corporation (acquired by Vertex Pharmaceuticals Inc). Before Aurora, Dr. Collinson held senior management positions at GlaxoWellcome, including Vice President of Gastrointestinal Diseases, and at Baxter International Inc.

Dr. Collinson is a director of Vertex Pharmaceuticals Inc. and several private companies.

Dr. Collinson was awarded an MBA from Harvard Business School and a Ph.D. in Physical Chemistry from the University of Oxford.

collinson@tiogapharma.com

David Urso
Chief Operating Officer and General Counsel

Prior to joining Tioga, Mr. Urso was a Principal at Forward Ventures. He has a scientific background in molecular immunology and is an attorney with experience in corporate securities and corporate partnering transactions in the life science industry.

Before joining Forward Ventures, Mr. Urso was Director of Corporate Development and Legal Affairs at DNA Sciences, Inc. Mr. Urso worked as an attorney in the corporate securities and technology transfer groups at Wilson Sonsini Goodrich & Rosati LLP and at Cooley Godward LLP; and as a bench scientist at SmithKline Beecham and the University of Pennsylvania Medical School.

Mr. Urso received a J.D. from Harvard Law School and a B.A. in Molecular Biology and Philosophy from Reed College.

urso@tiogapharma.com

Allen Mangel, M.D., Ph.D.
Chief Medical Officer (consultant)

Dr. Allen Mangel is a gastroenterologist and vice president of RTI Health Solutions. Following completion of his medical training, Dr. Mangel did his internship and residency in internal medicine at Duke University Medical Center and then completed his gastroenterology fellowship also at Duke. Following completion of his formal training, he remained on the faculty in the Department of Medicine, Division of Gastroenterology, at Duke for three years. Dr. Mangel also has a Ph.D. from the University of Illinois, where his research focused on control of electrical and mechanical activity in gastrointestinal smooth muscle.

Dr. Mangel has extensive pharmaceutical industry experience, including time at GlaxoSmithKline and Merck & Co. As the Head of Gastroenterology Clinical Development at GlaxoSmithKline, Dr. Mangel led the clinical development of drugs targeting gastrointestinal diseases, most notably irritable bowel syndrome. He has over 80 publications.

Gareth A. Hicks, Ph.D.
Chief Scientific Officer and Head of Scientific and Clinical Affairs

Dr. Hicks’s research in the fields of neurogastroenterology and neuroscience has focused primarily on irritable bowel syndrome and pain. Prior to joining Tioga, Dr. Hicks worked in the business development team at Ikaria, Inc. He was previously Head of US Clinical Development and Medical Affairs in Gastroenterology and Urology for Novartis Pharmaceuticals Corporation and prior to joining Novartis was Head of Gastrointestinal Disease Research for GlaxoSmithKline.

Before joining the pharmaceutical industry, Dr. Hicks was a Wellcome Trust Fellow at the The Vollum Institute in Portland, Oregon. Dr. Hicks received M.Phil. and Ph.D. degrees in Pharmacology from the University of Cambridge.

hicks@tiogapharma.com